Kringle Pharma (4884.T) Stock Price

Kringle Pharma Price

CLOSED
412.00JPY+1.00 (+0.24 %)
Market closed

Revenue at Kringle Pharma has contracted by 31.2% per year over the past 5 years to 72.22 M JPY. For Kringle Pharma, the net margin of -1,268.8% is down versus -103.9% a few years ago. The stock trades about 39% above its 52-week low.

Kringle Pharma stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Kringle Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Kringle Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Kringle Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Kringle Pharma Stock Price History
DateKringle Pharma Price
8/14/2026412.00 JPY
8/13/2026411.00 JPY
8/12/2026406.00 JPY
8/10/2026362.00 JPY
8/7/2026347.00 JPY
8/6/2026341.00 JPY
8/5/2026332.00 JPY
8/4/2026327.00 JPY
8/3/2026322.00 JPY
7/31/2026318.00 JPY
7/30/2026317.00 JPY
7/29/2026312.00 JPY
7/28/2026312.00 JPY
7/27/2026316.00 JPY
7/24/2026317.00 JPY
7/23/2026318.00 JPY
7/22/2026317.00 JPY
7/21/2026319.00 JPY
7/17/2026324.00 JPY
7/16/2026340.00 JPY
7/15/2026343.00 JPY
7/14/2026331.00 JPY
7/13/2026337.00 JPY
7/10/2026332.00 JPY
7/9/2026321.00 JPY
7/8/2026325.00 JPY
7/7/2026340.00 JPY
7/6/2026336.00 JPY
7/3/2026335.00 JPY
7/2/2026342.00 JPY
7/1/2026324.00 JPY
6/30/2026331.00 JPY
6/29/2026344.00 JPY
6/26/2026318.00 JPY
6/25/2026309.00 JPY
6/24/2026305.00 JPY
6/23/2026297.00 JPY
6/22/2026302.00 JPY
6/19/2026310.00 JPY
6/18/2026330.00 JPY
6/17/2026302.00 JPY
6/16/2026301.00 JPY
6/15/2026296.00 JPY
6/12/2026303.00 JPY
6/11/2026308.00 JPY
6/10/2026309.00 JPY
6/9/2026310.00 JPY
6/8/2026327.00 JPY
6/5/2026334.00 JPY
6/4/2026335.00 JPY
6/3/2026352.00 JPY
6/2/2026377.00 JPY
6/1/2026385.00 JPY
5/29/2026393.00 JPY
5/28/2026412.00 JPY
5/27/2026412.00 JPY
5/26/2026409.00 JPY
5/25/2026426.00 JPY
5/22/2026438.00 JPY
5/21/2026417.00 JPY
5/20/2026408.00 JPY
5/19/2026424.00 JPY
5/18/2026431.00 JPY
5/15/2026440.00 JPY
5/14/2026427.00 JPY
5/13/2026425.00 JPY
5/12/2026424.00 JPY
5/11/2026466.00 JPY
5/8/2026461.00 JPY
5/7/2026470.00 JPY
5/1/2026474.00 JPY
4/30/2026461.00 JPY
4/28/2026484.00 JPY
4/27/2026479.00 JPY
4/24/2026498.00 JPY
4/23/2026557.00 JPY
4/22/2026503.00 JPY
4/21/2026492.00 JPY
4/20/2026481.00 JPY
4/17/2026486.00 JPY
4/16/2026489.00 JPY
4/15/2026504.00 JPY
4/14/2026476.00 JPY
4/13/2026471.00 JPY
4/10/2026451.00 JPY
4/9/2026464.00 JPY
4/8/2026446.00 JPY
4/7/2026449.00 JPY
4/6/2026448.00 JPY
4/3/2026511.00 JPY
4/2/2026514.00 JPY
4/1/2026487.00 JPY
3/31/2026407.00 JPY
3/30/2026399.00 JPY
3/27/2026395.00 JPY
3/26/2026382.00 JPY
3/25/2026385.00 JPY
3/24/2026379.00 JPY
3/23/2026368.00 JPY
3/19/2026379.00 JPY
3/18/2026397.00 JPY
3/17/2026392.00 JPY
3/16/2026393.00 JPY
3/13/2026397.00 JPY
3/12/2026398.00 JPY
3/11/2026416.00 JPY
3/10/2026410.00 JPY
3/9/2026401.00 JPY
3/6/2026415.00 JPY
3/5/2026399.00 JPY
3/4/2026378.00 JPY
3/3/2026395.00 JPY
3/2/2026395.00 JPY
2/27/2026395.00 JPY
2/26/2026385.00 JPY
2/25/2026382.00 JPY
2/24/2026374.00 JPY
2/20/2026384.00 JPY
2/19/2026386.00 JPY
2/18/2026385.00 JPY
2/17/2026379.00 JPY
2/16/2026377.00 JPY
2/13/2026392.00 JPY
2/12/2026405.00 JPY
2/10/2026382.00 JPY
2/9/2026375.00 JPY
2/6/2026372.00 JPY
2/5/2026378.00 JPY
2/4/2026380.00 JPY
2/3/2026385.00 JPY
2/2/2026387.00 JPY
1/30/2026391.00 JPY
1/29/2026395.00 JPY
1/28/2026387.00 JPY
1/27/2026390.00 JPY
1/26/2026399.00 JPY
1/23/2026404.00 JPY
1/22/2026391.00 JPY
1/21/2026399.00 JPY
1/20/2026414.00 JPY
1/19/2026413.00 JPY
1/16/2026419.00 JPY
1/15/2026418.00 JPY
1/14/2026403.00 JPY
1/13/2026397.00 JPY
1/9/2026408.00 JPY
1/8/2026411.00 JPY
1/7/2026392.00 JPY
1/6/2026392.00 JPY
1/5/2026392.00 JPY
12/30/2025389.00 JPY
12/29/2025385.00 JPY
12/26/2025379.00 JPY
12/25/2025380.00 JPY
12/24/2025378.00 JPY
12/23/2025381.00 JPY
12/22/2025381.00 JPY
12/19/2025388.00 JPY
12/18/2025377.00 JPY
12/17/2025378.00 JPY
12/16/2025384.00 JPY
12/15/2025382.00 JPY
12/12/2025378.00 JPY
12/11/2025381.00 JPY
12/10/2025394.00 JPY
12/9/2025394.00 JPY
12/8/2025393.00 JPY
12/5/2025392.00 JPY
12/4/2025396.00 JPY
12/3/2025391.00 JPY
12/2/2025393.00 JPY
12/1/2025406.00 JPY
11/28/2025417.00 JPY
11/27/2025418.00 JPY
11/26/2025420.00 JPY
11/25/2025418.00 JPY
11/21/2025418.00 JPY
11/20/2025413.00 JPY
11/19/2025414.00 JPY
11/18/2025419.00 JPY
11/17/2025429.00 JPY
11/14/2025428.00 JPY
11/13/2025430.00 JPY
11/12/2025429.00 JPY
11/11/2025428.00 JPY
11/10/2025428.00 JPY
11/7/2025425.00 JPY
11/6/2025427.00 JPY
11/5/2025431.00 JPY
11/4/2025435.00 JPY
10/31/2025436.00 JPY
10/30/2025430.00 JPY
10/29/2025429.00 JPY
10/28/2025439.00 JPY
10/27/2025449.00 JPY
10/24/2025450.00 JPY
10/23/2025457.00 JPY
10/22/2025461.00 JPY
10/21/2025458.00 JPY
10/20/2025454.00 JPY
10/17/2025449.00 JPY
10/16/2025453.00 JPY
10/15/2025452.00 JPY
10/14/2025450.00 JPY
10/10/2025461.00 JPY
10/9/2025457.00 JPY
10/8/2025475.00 JPY
10/7/2025465.00 JPY
10/6/2025454.00 JPY
10/3/2025449.00 JPY
10/2/2025438.00 JPY
10/1/2025452.00 JPY
9/30/2025462.00 JPY
9/29/2025463.00 JPY
9/26/2025467.00 JPY
9/25/2025476.00 JPY
9/24/2025486.00 JPY
9/22/2025490.00 JPY
9/19/2025486.00 JPY
9/18/2025488.00 JPY
9/17/2025491.00 JPY
9/16/2025494.00 JPY
9/12/2025489.00 JPY
9/11/2025489.00 JPY
9/10/2025491.00 JPY
9/9/2025486.00 JPY
9/8/2025496.00 JPY
9/5/2025497.00 JPY
9/4/2025483.00 JPY
9/3/2025487.00 JPY
9/2/2025499.00 JPY
9/1/2025504.00 JPY
8/29/2025489.00 JPY
8/28/2025496.00 JPY
8/27/2025486.00 JPY
8/26/2025485.00 JPY
8/25/2025478.00 JPY
8/22/2025487.00 JPY
8/21/2025483.00 JPY
8/20/2025493.00 JPY
8/19/2025496.00 JPY
8/18/2025493.00 JPY
Access this data via the Eulerpool API
Get Free API Key

Kringle Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
0.00 JPY
-223.61 M JPY
-64.55 M JPY
Jan 1, 2019
0.00 JPY
-371.74 M JPY
-302.05 M JPY
Jan 1, 2020
467.62 M JPY
-171.60 M JPY
-117.83 M JPY
Jan 1, 2021
289.76 M JPY
-357.88 M JPY
-301.17 M JPY
Jan 1, 2022
391.83 M JPY
-426.17 M JPY
-331.83 M JPY
Jan 1, 2023
69.25 M JPY
-888.76 M JPY
-854.15 M JPY
Jan 1, 2024
80.04 M JPY
-817.88 M JPY
-756.45 M JPY
Jan 1, 2025
72.22 M JPY
-909.45 M JPY
-916.26 M JPY

Kringle Pharma Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 16, 2026, 9:01 PM
 
REVENUEM JPY
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM JPY
EBITM JPY
EBIT MARGIN%
NET INCOMEM JPY
NET INCOME GROWTH%
SHARESM
20182019202020212022202320242025
––467.00289.00391.0069.0080.0072.00
–––-38.1235.29-82.3515.94-10.00
––100.0075.4377.49439.13378.75420.83
303.00303.00467.00218.00303.00303.00303.00303.00
-223.00-371.00-171.00-357.00-426.00-888.00-817.00-909.00
––-36.62-123.53-108.95-1,286.96-1,021.25-1,262.50
-64.00-302.00-117.00-301.00-331.00-854.00-756.00-916.00
–371.88-61.26157.269.97158.01-11.4821.16
1.041.041.104.154.865.396.406.84
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Kringle Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Kringle Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Kringle Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Kringle Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Kringle Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Kringle Pharma stock margins

The Kringle Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kringle Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kringle Pharma.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
77.44 %
- %
- %
Jan 1, 2019
77.44 %
- %
- %
Jan 1, 2020
100.00 %
-36.70 %
-25.20 %
Jan 1, 2021
75.29 %
-123.51 %
-103.94 %
Jan 1, 2022
77.44 %
-108.76 %
-84.69 %
Jan 1, 2023
77.44 %
-1,283.41 %
-1,233.43 %
Jan 1, 2024
77.44 %
-1,021.87 %
-945.12 %
Jan 1, 2025
77.44 %
-1,259.37 %
-1,268.79 %

Kringle Pharma Stock Revenue, EBIT, Earnings per Share

The Kringle Pharma earnings per share therefore indicates how much revenue Kringle Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.00 JPY
-214.78 JPY
-62.01 JPY
Jan 1, 2019
0.00 JPY
-357.07 JPY
-290.13 JPY
Jan 1, 2020
423.45 JPY
-155.40 JPY
-106.70 JPY
Jan 1, 2021
69.76 JPY
-86.16 JPY
-72.51 JPY
Jan 1, 2022
80.69 JPY
-87.76 JPY
-68.34 JPY
Jan 1, 2023
12.85 JPY
-164.88 JPY
-158.46 JPY
Jan 1, 2024
12.51 JPY
-127.81 JPY
-118.21 JPY
Jan 1, 2025
10.55 JPY
-132.92 JPY
-133.92 JPY

Kringle Pharma business model & stock analysis

Kringle Pharma Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Kringle Pharma historical P/E ratio, EBIT multiple, and P/S ratio

Kringle Pharma annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Kringle Pharma shares outstanding

The number of shares of Kringle Pharma was 6.84 M in 2025. This indicates how many shares Kringle Pharma is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
1.04 M Stocks
Jan 1, 2019
1.04 M Stocks
Jan 1, 2020
1.10 M Stocks
Jan 1, 2021
4.15 M Stocks
Jan 1, 2022
4.86 M Stocks
Jan 1, 2023
5.39 M Stocks
Jan 1, 2024
6.40 M Stocks
Jan 1, 2025
6.84 M Stocks
Price targets and forecasts for Kringle Pharma are not yet available.

Kringle Pharma shareholder structure

% Name
6.81415%
Nippon Zenyaku Kogyo Co., Ltd.
Nippon Zenyaku Kogyo Co., Ltd.
4.16735%
Evolution Capital Management, LLC
Evolution Capital Management, LLC
2.72109%
CYBERDYNE, Inc.
CYBERDYNE, Inc.
2.40816%
Yamada (Tetsuo)
Yamada (Tetsuo)
1.66054%
Nomura Securities Co., Ltd.
Nomura Securities Co., Ltd.
1.63673%
Takayama (Jiro)
Takayama (Jiro)

Kringle Pharma Beneficial Ownership Filings (SEC 13D/G)

Free Float
85.9%
Float Shares
-
Shares Outstanding
-

Kringle Pharma Executives and Management Board

7 members · avg. age 56 · 0 % women

Management

KA

Dr. Kiichi Adachi (54)

President, Chief Executive Officer, Representative Director · since 2004

–

Board of Directors

KM

Mr. Koichi Murakami (62)

Director of Business Administration, Director · since 2021

–
DH

Mr. Daishin Hayata (47)

Director of Pharmaceutical Development, Director · since 2022

–
YC

Mr. Yoshiyuki Chino

Director

–
AT

Dr. Akihiro Tomoyasu (52)

Director

–
MF

Dr. Masato Fukui (46)

Independent Director

–
KY

Mr. Koichiro Yoshino (73)

Independent Director

–

Kringle Pharma Supply Chain

Kringle Pharma Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#NameTrend
1
Toho
Supplier·Customer·Health Care Providers & Services·JP
-0.33
0.21
-0.69
-0.18
-0.11
—

Frequently asked questions about Kringle Pharma

Converted at the current exchange rate, the Kringle Pharma share trades at 2.24 EUR (412.00 JPY).

No history available for Kringle Pharma.

The revenue cannot currently be calculated for Kringle Pharma.

The profit cannot currently be calculated for Kringle Pharma.

The P/E ratio cannot be calculated for Kringle Pharma at the moment.

The P/S cannot be calculated for Kringle Pharma currently.

The Eulerpool Quality Score for Kringle Pharma is 2/10.

The ISIN of Kringle Pharma is JP3270790003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Kringle Pharma is 4884.T. The ticker symbol is used to trade Kringle Pharma shares on the stock exchange.

Kringle Pharma paid dividends every year for the past 0 years.

Kringle Pharma is assigned to the 'Health' sector.

The dividends of Kringle Pharma are distributed in JPY.

All fundamentals and in-depth analysis of Kringle Pharma

Our stock analysis for Kringle Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kringle Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Kringle Pharma Stock
Kringle Pharma Revenue→
Kringle Pharma Stock
Kringle Pharma Net Income→
Kringle Pharma Stock
Kringle Pharma P/E→
Kringle Pharma Stock
Kringle Pharma P/S→
Kringle Pharma Stock
Kringle Pharma EBIT→
Kringle Pharma Stock
Kringle Pharma Dividend→
Kringle Pharma Stock
Kringle Pharma Directors Dealings→
Kringle Pharma Stock
Kringle Pharma Stocks→
Kringle Pharma Stock
Kringle Pharma Market capitalization→
Kringle Pharma Stock
Kringle Pharma Debt→
Kringle Pharma Stock
Kringle Pharma Liabilities→
Kringle Pharma Stock
Kringle Pharma Equity→
Kringle Pharma Stock
Kringle Pharma AAQS→
Kringle Pharma Stock
Kringle Pharma Employees→
Kringle Pharma Stock
Kringle Pharma ROE→
Kringle Pharma Stock
Kringle Pharma ROA→
Kringle Pharma Stock
Kringle Pharma ROCE→
Kringle Pharma Stock
Kringle Pharma News→
Kringle Pharma Stock
Kringle Pharma Analyst Price Targets→

Health Stocks

Krishna Institute of Medical SciencesKrebs Biochemicals and IndustriesKrsnaa DiagnosticsKPC PharmaceuticalsKrystal BiotechKowa CoKT Medical Service CoKovai Medical Center and HospitalKubota Pharmaceutical Holdings CoKORU Medical SystemsKukje Pharma CoKorro BioAll Stocks A–Z →